APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spinal Muscular Atrophy Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Spinal Muscular Atrophy Medicine Market Outlook and Growth Opportunities 2026

26 December 2025208 pages

Choose your research edition.

Industry ResearchSpinal Muscular Atrophy Medicine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal Muscular Atrophy Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Spinal Muscular Atrophy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal Muscular Atrophy Medicine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal Muscular Atrophy Medicine Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Spinal Muscular Atrophy Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Spinal Muscular Atrophy Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Spinal Muscular Atrophy Medicine market include Novartis AG, Astellas Pharma Inc., WAVE Life Sciences Ltd., Vybion, Inc., Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neurotune AG, Neurodyn Inc. and Longevity Biotech, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Spinal Muscular Atrophy Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Spinal Muscular Atrophy Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Spinal Muscular Atrophy Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Spinal Muscular Atrophy Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Spinal Muscular Atrophy Medicine Segment by Company

Novartis AG

Astellas Pharma Inc.

WAVE Life Sciences Ltd.

Vybion, Inc.

Voyager Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Neurotune AG

Neurodyn Inc.

Longevity Biotech, Inc

Ionis Pharmaceuticals, Inc.

GMP-Orphan SAS

Genzyme Corporation

Genethon

F. Hoffmann-La Roche Ltd.

Cytokinetics, Inc. 24

Bioblast Pharma Ltd.

AveXis, Inc.

Spinal Muscular Atrophy Medicine Segment by Type

LMI-070

ND-602

NT-1654

NXD-30001

Nusinersen

Others

Spinal Muscular Atrophy Medicine Segment by Application

Hospital

Clinic

Others

Spinal Muscular Atrophy Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Spinal Muscular Atrophy Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Spinal Muscular Atrophy Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Spinal Muscular Atrophy Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Spinal Muscular Atrophy Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal Muscular Atrophy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal Muscular Atrophy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal Muscular Atrophy Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Spinal Muscular Atrophy Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Spinal Muscular Atrophy Medicine industry.

Chapter 3: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Spinal Muscular Atrophy Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Spinal Muscular Atrophy Medicine Industry Trends Table 2. Spinal Muscular Atrophy Medicine Industry Drivers Table 3. Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges Table 4. Spinal Muscular Atrophy Medicine Industry Restraints Table 5. Global Spinal Muscular Atrophy Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Spinal Muscular Atrophy Medicine Revenue Share by Company (2021-2026) Table 7. Global Spinal Muscular Atrophy Medicine Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Company (2021-2026) Table 9. Global Spinal Muscular Atrophy Medicine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Spinal Muscular Atrophy Medicine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Spinal Muscular Atrophy Medicine Key Company Manufacturing Base & Headquarters Table 12. Global Spinal Muscular Atrophy Medicine Company, Product Type & Application Table 13. Global Spinal Muscular Atrophy Medicine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of LMI-070 Table 18. Significant Companies of ND-602 Table 19. Significant Companies of NT-1654 Table 20. Significant Companies of NXD-30001 Table 21. Significant Companies of Nusinersen Table 22. Significant Companies of Others Table 23. Global Spinal Muscular Atrophy Medicine Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Type (2021-2026) Table 27. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Type (2027-2032) Table 28. Global Spinal Muscular Atrophy Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Spinal Muscular Atrophy Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Spinal Muscular Atrophy Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Spinal Muscular Atrophy Medicine Sales Value Share by Type (2021-2026) Table 32. Global Spinal Muscular Atrophy Medicine Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Table 34. Significant Companies of Clinic Table 35. Significant Companies of Others Table 36. Global Spinal Muscular Atrophy Medicine Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Application (2021-2026) Table 40. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Application (2027-2032) Table 41. Global Spinal Muscular Atrophy Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Spinal Muscular Atrophy Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Spinal Muscular Atrophy Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Spinal Muscular Atrophy Medicine Sales Value Share by Application (2021-2026) Table 45. Global Spinal Muscular Atrophy Medicine Sales Value Share by Application (2027-2032) Table 46. Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (W Units) Table 48. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026) Table 49. Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032) & (W Units) Table 50. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2027-2032) Table 51. Global Spinal Muscular Atrophy Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Spinal Muscular Atrophy Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Spinal Muscular Atrophy Medicine Sales Value Share by Region (2021-2026) Table 54. Global Spinal Muscular Atrophy Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Spinal Muscular Atrophy Medicine Sales Value Share by Region (2027-2032) Table 56. Global Spinal Muscular Atrophy Medicine Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Spinal Muscular Atrophy Medicine Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Spinal Muscular Atrophy Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 61. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026) Table 62. Global Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 63. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country (2027-2032) Table 64. Global Spinal Muscular Atrophy Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Spinal Muscular Atrophy Medicine Sales Value Market Share by Country (2021-2026) Table 66. Global Spinal Muscular Atrophy Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Spinal Muscular Atrophy Medicine Sales Value Market Share by Country (2027-2032) Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio Table 72. Novartis AG Recent Development Table 73. Astellas Pharma Inc. Company Information Table 74. Astellas Pharma Inc. Business Overview Table 75. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 77. Astellas Pharma Inc. Recent Development Table 78. WAVE Life Sciences Ltd. Company Information Table 79. WAVE Life Sciences Ltd. Business Overview Table 80. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 82. WAVE Life Sciences Ltd. Recent Development Table 83. Vybion, Inc. Company Information Table 84. Vybion, Inc. Business Overview Table 85. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 87. Vybion, Inc. Recent Development Table 88. Voyager Therapeutics, Inc. Company Information Table 89. Voyager Therapeutics, Inc. Business Overview Table 90. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 92. Voyager Therapeutics, Inc. Recent Development Table 93. Sarepta Therapeutics, Inc. Company Information Table 94. Sarepta Therapeutics, Inc. Business Overview Table 95. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 97. Sarepta Therapeutics, Inc. Recent Development Table 98. Neurotune AG Company Information Table 99. Neurotune AG Business Overview Table 100. Neurotune AG Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio Table 102. Neurotune AG Recent Development Table 103. Neurodyn Inc. Company Information Table 104. Neurodyn Inc. Business Overview Table 105. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 107. Neurodyn Inc. Recent Development Table 108. Longevity Biotech, Inc Company Information Table 109. Longevity Biotech, Inc Business Overview Table 110. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio Table 112. Longevity Biotech, Inc Recent Development Table 113. Ionis Pharmaceuticals, Inc. Company Information Table 114. Ionis Pharmaceuticals, Inc. Business Overview Table 115. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 117. Ionis Pharmaceuticals, Inc. Recent Development Table 118. GMP-Orphan SAS Company Information Table 119. GMP-Orphan SAS Business Overview Table 120. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio Table 122. GMP-Orphan SAS Recent Development Table 123. Genzyme Corporation Company Information Table 124. Genzyme Corporation Business Overview Table 125. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio Table 127. Genzyme Corporation Recent Development Table 128. Genethon Company Information Table 129. Genethon Business Overview Table 130. Genethon Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Genethon Spinal Muscular Atrophy Medicine Product Portfolio Table 132. Genethon Recent Development Table 133. F. Hoffmann-La Roche Ltd. Company Information Table 134. F. Hoffmann-La Roche Ltd. Business Overview Table 135. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 137. F. Hoffmann-La Roche Ltd. Recent Development Table 138. Cytokinetics, Inc. 24 Company Information Table 139. Cytokinetics, Inc. 24 Business Overview Table 140. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio Table 142. Cytokinetics, Inc. 24 Recent Development Table 143. Bioblast Pharma Ltd. Company Information Table 144. Bioblast Pharma Ltd. Business Overview Table 145. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 147. Bioblast Pharma Ltd. Recent Development Table 148. AveXis, Inc. Company Information Table 149. AveXis, Inc. Business Overview Table 150. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 152. AveXis, Inc. Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Spinal Muscular Atrophy Medicine Distributors List Table 156. Spinal Muscular Atrophy Medicine Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Spinal Muscular Atrophy Medicine Product Image Figure 2. Global Spinal Muscular Atrophy Medicine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spinal Muscular Atrophy Medicine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Spinal Muscular Atrophy Medicine Sales (2021-2032) & (W Units) Figure 5. Global Spinal Muscular Atrophy Medicine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Spinal Muscular Atrophy Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. LMI-070 Image Figure 10. ND-602 Image Figure 11. NT-1654 Image Figure 12. NXD-30001 Image Figure 13. Nusinersen Image Figure 14. Others Image Figure 15. Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Spinal Muscular Atrophy Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Type (2021-2032) Figure 18. Global Spinal Muscular Atrophy Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Spinal Muscular Atrophy Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Spinal Muscular Atrophy Medicine Sales Value Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Spinal Muscular Atrophy Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Spinal Muscular Atrophy Medicine Sales Volume Share by Application (2021-2032) Figure 27. Global Spinal Muscular Atrophy Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Spinal Muscular Atrophy Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Spinal Muscular Atrophy Medicine Sales Value Share by Application (2021-2032) Figure 30. Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Spinal Muscular Atrophy Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Spinal Muscular Atrophy Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Spinal Muscular Atrophy Medicine Sales Value (2021-2032) & (US$ Million) Figure 35. North America Spinal Muscular Atrophy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Spinal Muscular Atrophy Medicine Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Spinal Muscular Atrophy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Spinal Muscular Atrophy Medicine Sales Value (2021-2032) & (US$ Million) Figure 41. South America Spinal Muscular Atrophy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Spinal Muscular Atrophy Medicine Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Spinal Muscular Atrophy Medicine Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • LMI-070
  • ND-602
  • NT-1654
  • NXD-30001
  • Nusinersen
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Astellas Pharma Inc.
  • WAVE Life Sciences Ltd.
  • Vybion, Inc.
  • Voyager Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Neurotune AG
  • Neurodyn Inc.
  • Longevity Biotech, Inc
  • Ionis Pharmaceuticals, Inc.
  • GMP-Orphan SAS
  • Genzyme Corporation
  • Genethon
  • F. Hoffmann-La Roche Ltd.
  • Cytokinetics, Inc. 24
  • Bioblast Pharma Ltd.
  • AveXis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Spinal Muscular Atrophy Medicine Sales Value (2021-2032)
  4. 1.2.2 Global Spinal Muscular Atrophy Medicine Sales Volume (2021-2032)
  5. 1.2.3 Global Spinal Muscular Atrophy Medicine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Spinal Muscular Atrophy Medicine Market Dynamics
  1. 2.1 Spinal Muscular Atrophy Medicine Industry Trends
  2. 2.2 Spinal Muscular Atrophy Medicine Industry Drivers
  3. 2.3 Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges
  4. 2.4 Spinal Muscular Atrophy Medicine Industry Restraints
3 Spinal Muscular Atrophy Medicine Market by Company
  1. 3.1 Global Spinal Muscular Atrophy Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Spinal Muscular Atrophy Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Spinal Muscular Atrophy Medicine Sales Volume by Company (2021-2026)
  4. 3.4 Global Spinal Muscular Atrophy Medicine Average Price by Company (2021-2026)
  5. 3.5 Global Spinal Muscular Atrophy Medicine Company Ranking (2024-2026)
  6. 3.6 Global Spinal Muscular Atrophy Medicine Company Manufacturing Base and Headquarters
  7. 3.7 Global Spinal Muscular Atrophy Medicine Company Product Type and Application
  8. 3.8 Global Spinal Muscular Atrophy Medicine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Spinal Muscular Atrophy Medicine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Spinal Muscular Atrophy Medicine Market by Type
  1. 4.1 Spinal Muscular Atrophy Medicine Type Introduction
  2. 4.1.1 LMI-070
  3. 4.1.2 ND-602
  4. 4.1.3 NT-1654
  5. 4.1.4 NXD-30001
  6. 4.1.5 Nusinersen
  7. 4.1.6 Others
  8. 4.2 Global Spinal Muscular Atrophy Medicine Sales Volume by Type
  9. 4.2.1 Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Spinal Muscular Atrophy Medicine Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Spinal Muscular Atrophy Medicine Sales Value by Type
  13. 4.3.1 Global Spinal Muscular Atrophy Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Spinal Muscular Atrophy Medicine Sales Value by Type (2021-2032)
  15. 4.3.3 Global Spinal Muscular Atrophy Medicine Sales Value Share by Type (2021-2032)
5 Spinal Muscular Atrophy Medicine Market by Application
  1. 5.1 Spinal Muscular Atrophy Medicine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Spinal Muscular Atrophy Medicine Sales Volume by Application
  6. 5.2.1 Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Spinal Muscular Atrophy Medicine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Spinal Muscular Atrophy Medicine Sales Value by Application
  10. 5.3.1 Global Spinal Muscular Atrophy Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Spinal Muscular Atrophy Medicine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Spinal Muscular Atrophy Medicine Sales Value Share by Application (2021-2032)
6 Spinal Muscular Atrophy Medicine Regional Sales and Value Analysis
  1. 6.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021-2026
  4. 6.2.2 Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032)
  5. 6.3 Global Spinal Muscular Atrophy Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Spinal Muscular Atrophy Medicine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Spinal Muscular Atrophy Medicine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Spinal Muscular Atrophy Medicine Sales Value by Region (2027-2032)
  9. 6.5 Global Spinal Muscular Atrophy Medicine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Spinal Muscular Atrophy Medicine Sales Value (2021-2032)
  12. 6.6.2 North America Spinal Muscular Atrophy Medicine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Spinal Muscular Atrophy Medicine Sales Value (2021-2032)
  15. 6.7.2 Europe Spinal Muscular Atrophy Medicine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Spinal Muscular Atrophy Medicine Sales Value (2021-2032)
  21. 6.9.2 South America Spinal Muscular Atrophy Medicine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value Share by Country, 2025 VS 2032
7 Spinal Muscular Atrophy Medicine Country-level Sales and Value Analysis
  1. 7.1 Global Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Spinal Muscular Atrophy Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  4. 7.3.1 Global Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
  5. 7.3.2 Global Spinal Muscular Atrophy Medicine Sales by Country (2027-2032)
  6. 7.4 Global Spinal Muscular Atrophy Medicine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Spinal Muscular Atrophy Medicine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Spinal Muscular Atrophy Medicine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Spinal Muscular Atrophy Medicine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Spinal Muscular Atrophy Medicine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Spinal Muscular Atrophy Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Astellas Pharma Inc.
  8. 8.2.1 Astellas Pharma Inc. Company Information
  9. 8.2.2 Astellas Pharma Inc. Business Overview
  10. 8.2.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  12. 8.2.5 Astellas Pharma Inc. Recent Developments
  13. 8.3 WAVE Life Sciences Ltd.
  14. 8.3.1 WAVE Life Sciences Ltd. Company Information
  15. 8.3.2 WAVE Life Sciences Ltd. Business Overview
  16. 8.3.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  18. 8.3.5 WAVE Life Sciences Ltd. Recent Developments
  19. 8.4 Vybion, Inc.
  20. 8.4.1 Vybion, Inc. Company Information
  21. 8.4.2 Vybion, Inc. Business Overview
  22. 8.4.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  24. 8.4.5 Vybion, Inc. Recent Developments
  25. 8.5 Voyager Therapeutics, Inc.
  26. 8.5.1 Voyager Therapeutics, Inc. Company Information
  27. 8.5.2 Voyager Therapeutics, Inc. Business Overview
  28. 8.5.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  30. 8.5.5 Voyager Therapeutics, Inc. Recent Developments
  31. 8.6 Sarepta Therapeutics, Inc.
  32. 8.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 8.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 8.6.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  36. 8.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 8.7 Neurotune AG
  38. 8.7.1 Neurotune AG Company Information
  39. 8.7.2 Neurotune AG Business Overview
  40. 8.7.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
  42. 8.7.5 Neurotune AG Recent Developments
  43. 8.8 Neurodyn Inc.
  44. 8.8.1 Neurodyn Inc. Company Information
  45. 8.8.2 Neurodyn Inc. Business Overview
  46. 8.8.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  48. 8.8.5 Neurodyn Inc. Recent Developments
  49. 8.9 Longevity Biotech, Inc
  50. 8.9.1 Longevity Biotech, Inc Company Information
  51. 8.9.2 Longevity Biotech, Inc Business Overview
  52. 8.9.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
  54. 8.9.5 Longevity Biotech, Inc Recent Developments
  55. 8.10 Ionis Pharmaceuticals, Inc.
  56. 8.10.1 Ionis Pharmaceuticals, Inc. Company Information
  57. 8.10.2 Ionis Pharmaceuticals, Inc. Business Overview
  58. 8.10.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  60. 8.10.5 Ionis Pharmaceuticals, Inc. Recent Developments
  61. 8.11 GMP-Orphan SAS
  62. 8.11.1 GMP-Orphan SAS Company Information
  63. 8.11.2 GMP-Orphan SAS Business Overview
  64. 8.11.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
  66. 8.11.5 GMP-Orphan SAS Recent Developments
  67. 8.12 Genzyme Corporation
  68. 8.12.1 Genzyme Corporation Company Information
  69. 8.12.2 Genzyme Corporation Business Overview
  70. 8.12.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
  72. 8.12.5 Genzyme Corporation Recent Developments
  73. 8.13 Genethon
  74. 8.13.1 Genethon Company Information
  75. 8.13.2 Genethon Business Overview
  76. 8.13.3 Genethon Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
  78. 8.13.5 Genethon Recent Developments
  79. 8.14 F. Hoffmann-La Roche Ltd.
  80. 8.14.1 F. Hoffmann-La Roche Ltd. Company Information
  81. 8.14.2 F. Hoffmann-La Roche Ltd. Business Overview
  82. 8.14.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  84. 8.14.5 F. Hoffmann-La Roche Ltd. Recent Developments
  85. 8.15 Cytokinetics, Inc. 24
  86. 8.15.1 Cytokinetics, Inc. 24 Company Information
  87. 8.15.2 Cytokinetics, Inc. 24 Business Overview
  88. 8.15.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
  90. 8.15.5 Cytokinetics, Inc. 24 Recent Developments
  91. 8.16 Bioblast Pharma Ltd.
  92. 8.16.1 Bioblast Pharma Ltd. Company Information
  93. 8.16.2 Bioblast Pharma Ltd. Business Overview
  94. 8.16.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  96. 8.16.5 Bioblast Pharma Ltd. Recent Developments
  97. 8.17 AveXis, Inc.
  98. 8.17.1 AveXis, Inc. Company Information
  99. 8.17.2 AveXis, Inc. Business Overview
  100. 8.17.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  102. 8.17.5 AveXis, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Spinal Muscular Atrophy Medicine Value Chain Analysis
  2. 9.1.1 Spinal Muscular Atrophy Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Spinal Muscular Atrophy Medicine Sales Mode & Process
  6. 9.2 Spinal Muscular Atrophy Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Spinal Muscular Atrophy Medicine Distributors
  9. 9.2.3 Spinal Muscular Atrophy Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst